Yes, 1-2 did well on a lower dose, like half dose or less but at full dose the odds and side effects one might best allow for a Plan B ready in the wings.PeterG
from earlier thread ... I have been dealing with hand-foot effects of Xeloda for years. The Oxi is bringing this to a new level. Short-term disability for a person with lung mets on palliative chemo who needs insurance to pay for treatment is really not a possibility. Nor is it psychologically or economically feasible for me to stop working.
There's a lot of fundamentals you haven't mentioned here, things that would help compare experience and plans. e.g. KRAS/BRAF/MSS, CEA, CA199, WBC etc
. But given the overall odds and your need for functionality, instead of oxi-Avastin added to 5FU, we've been happy with oral 5FU prodrug, celecoxib, targeted cimetidine, baby aspirin, IV vitamin C and powerful supplements, where most people apparently never see potent levels, consistently across the board. Back when you were hearing esoterica
from Chang and Nesselhut, I had hoped they would offer more hard hitting, basic integrative formulas, but apparently not. I feel like we've had better results with our artillery tactics - aim [bloodwork and path], fire, spot the next shot [based on bloodwork, eventually scan, change the shell type, size, powder, aim], fire...
Basically you would need to intensify Dr Lin's ADAPT formula enough for the 5FU to work again or slow this stuff down, without the side effects of oxi- and Avastin. Our answer for prevention of hand foot syndome was two fold: IV vitamin C and a different 5FU drug, tegafur-uracil, that is made in Taiwan, Korea, India, China, Japan (still?) and Europe(still?), perhaps available in Mexico (it's listed in their national formulary). My wife plays the piano after almost 8 years of chemo, that's not likely with Folfox. I've seen published mentions of IV vitamin C suppressing Xeloda's external effects, but we added other supplements too, to repair internal toxicities (5FU-folic acid). Even without the extras, Lin's earlier ADAPT patients had remarkable survivals despite mCRC and prior failures e.g. median OS headed over 8 years.